Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AERISTO COPD bronchodilator comparison study
2016-004655-75Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Glycopyrronium + formoterol fumarate fixed-dose combination with Umeclidinium + vilanterol fixed-dose combination (2 arms). Primary endpoint: Change from baseline in morning pre-dose trough FEV1. Started Mar 2017; status: completed.
02
Drugs
glycopyrroniumformoterolumeclidiniumvilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2016-004655-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004655-75.